62 filings
Page 2 of 4
8-K
0gumwwxi1djuee
14 Jun 23
Regulation FD Disclosure
8:53am
8-K
mqgft7
12 May 23
Regulation FD Disclosure
5:17pm
8-K
e15tt6h4y4439f3gn7
28 Apr 23
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
9:04am
8-K
f8a1zfgtt2xgt68l
19 Apr 23
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
5:05pm
8-K
59j2o9
14 Apr 23
Regulation FD Disclosure
8:58am
8-K
vwdzao1d1pv8xs
4 Apr 23
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
9:34am
8-K
aeuplwx
31 Mar 23
SAB Biotherapeutics Provides Company Update for Full Year 2022
5:12pm
8-K
8h1s6941b1wb0
24 Mar 23
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
5:19pm
8-K
t6fv io64z
7 Feb 23
Regulation FD Disclosure
9:03am
8-K
spr8b8 x8576rxe2a1
27 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
8-K
5rrom7
10 Jan 23
Regulation FD Disclosure
9:00am
8-K
kxtp0g12pihsvt qs
9 Jan 23
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
9:01am
8-K
zcpa6l
5 Jan 23
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
4:23pm
8-K
czi4k74x76wcm 6pv6
12 Dec 22
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
9:07am
8-K
h37y4ior56tvm9t
21 Nov 22
Regulation FD Disclosure
4:46pm
8-K
rj8 9gpzztv7n
7 Nov 22
Regulation FD Disclosure
9:30am
8-K
4sb9o5m58zvk57dhp aq
1 Nov 22
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership
5:06pm
8-K
jz7ad3dfqz rhw5ds
13 Oct 22
Entry into a Material Definitive Agreement
5:17pm
8-K
7p6p0finr10
7 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:09pm
8-K
eecpmgpw
30 Sep 22
Regulation FD Disclosure
9:12am